Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and PK of LPM3480392 Injection in Healthy Subjects
NCT05857449Phase 1Completed
- Sponsor
- Luye Pharma Group
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of LPM3480392 in postoperative pain and cancer pain (2 arms), sponsored by Luye Pharma Group. Primary endpoints: Incidents of Adverse Events (AE) including Serious Adverse Events (SAE), Drug Effects Questionnaire scores and 1 more. Started Nov 2021; status: completed.
02
Drugs
LPM3480392
03
Conditions
postoperative paincancer pain
Beyond the preview
Go deeper on NCT05857449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05857449.